Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
Open Access
- 15 December 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1071383
Abstract
Background: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit.Case presentation: We report a case of an elderly woman diagnosed with stage IIIC high-grade serous ovarian cancer (HGSOC). During a follow-up time of 6 years, the patient initially received multiple sequential courses of chemotherapy with platinum-based regimens and with no maintenance therapy. Similar to most patients with advanced HGSOC, she developed platinum resistance and experienced poor treatment results with a short progression-free survival (PFS). Ultimately, we gave the patient traditional non-platinum-based chemotherapy with bevacizumab and high-dose-rate interstitial brachytherapy followed by olaparib as a maintenance therapy. Up to now, the patient did response well to the treatment, and the PFS had exceeded 12 months.Conclusion: High-dose-rate interstitial brachytherapy combination with PARP inhibitors may be an option for isolated chemoresistant recurrent epithelial ovarian cancer.Keywords
This publication has 40 references indexed in Scilit:
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- Ovarian cancerThe Lancet, 2014
- Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian CancerJNCI: Journal of the National Cancer Institute, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Involved-field radiation therapy for locoregionally recurrent ovarian cancerGynecologic Oncology, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology GroupGynecologic Oncology, 2011
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Radiosensitivity of multicellular tumour spheroids obtained from human ovarian cancersEuropean Journal of Cancer, 1995
- Analysis of complications in patients treated with abdominopelvic radiation therapy for ovarian carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992